Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer

IntroductionColorectal cancer (CRC) is a leading cause of cancer-related mortality globally. Although tumor immunotherapy is widely recognized for treating unresectable CRC, challenges such as ineffective immunotherapy and drug resistance remain prevalent. While intratumor microbiome-derived butyrat...

Full description

Saved in:
Bibliographic Details
Main Authors: Linsheng Xu, Bingde Hu, Jingli He, Xin Fu, Na Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1510851/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841528019030638592
author Linsheng Xu
Linsheng Xu
Bingde Hu
Jingli He
Xin Fu
Na Liu
author_facet Linsheng Xu
Linsheng Xu
Bingde Hu
Jingli He
Xin Fu
Na Liu
author_sort Linsheng Xu
collection DOAJ
description IntroductionColorectal cancer (CRC) is a leading cause of cancer-related mortality globally. Although tumor immunotherapy is widely recognized for treating unresectable CRC, challenges such as ineffective immunotherapy and drug resistance remain prevalent. While intratumor microbiome-derived butyrate has been implicated in promoting lung cancer metastasis, its role in CRC chemoresistance is not well understood. This study aimed to explore the relationship between intratumor butyrate and chemoresistance in CRC.MethodsWe performed a comprehensive analysis of the microbiome composition in CRC patients with varying resistance-free survival (RFS) durations, utilizing 16S rRNA sequencing. Furthermore, we assessed the prognostic significance of circulating microbiome DNA (cmDNA) and examined the effects of exogenous butyrate supplementation on the chemosensitivity of CRC cell lines.ResultsOur 16S sequencing analysis revealed a reduction in microbial diversity within tumor samples of patients with resistance, as indicated by metrics such as observed taxonomic units, Shannon, and Simpson indices. Notably, Roseburia and Fusobacteria emerged as prominent biomarkers for the resistance group, whereas Bifidobacterium, Helicobacter, and Akkermansia were identified as biomarkers for the non-resistant group. Utilizing a Lasso regression model, we identified six genera-Roseburia, Helicobacter, Gardnerella, Flavonifractor, Coprococcus, and Anaerostipes-that significantly correlated with recurrence-free survival. Furthermore, both the intratumor microbiome signature and circulating microbiome DNA were effective in accurately predicting CRC resistance. Experimental assays, including CCK8 and wound-healing, demonstrated that intratumor microbiome-derived butyrate enhances the proliferation and migration of HCT15 cells in a time- and concentration-dependent manner. Cell survival analysis further indicated that butyrate treatment significantly increased the IC50 value, suggesting heightened drug resistance in HCT15 cells. Mechanistically, this resistance was attributed to butyrate’s activation of the PI3K-AKT signaling pathway.ConclusionOur results suggest that intratumor microbiome-derived butyrate contributes to chemoresistance in colorectal cancer, highlighting the potential prognostic and therapeutic significance of the intratumor microbiome.
format Article
id doaj-art-b2da95c27fa44af0afc8d624a49886bc
institution Kabale University
issn 1663-9812
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-b2da95c27fa44af0afc8d624a49886bc2025-01-15T04:11:07ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.15108511510851Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancerLinsheng Xu0Linsheng Xu1Bingde Hu2Jingli He3Xin Fu4Na Liu5Department of Gastroenterology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Gastroenterology, Anqing 116 Hospital, Anqing, ChinaDepartment of Gastroenterology, Anqing 116 Hospital, Anqing, ChinaDepartment of Gastroenterology, Anqing 116 Hospital, Anqing, ChinaDepartment of Gastroenterology, Anqing 116 Hospital, Anqing, ChinaDepartment of Gastroenterology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaIntroductionColorectal cancer (CRC) is a leading cause of cancer-related mortality globally. Although tumor immunotherapy is widely recognized for treating unresectable CRC, challenges such as ineffective immunotherapy and drug resistance remain prevalent. While intratumor microbiome-derived butyrate has been implicated in promoting lung cancer metastasis, its role in CRC chemoresistance is not well understood. This study aimed to explore the relationship between intratumor butyrate and chemoresistance in CRC.MethodsWe performed a comprehensive analysis of the microbiome composition in CRC patients with varying resistance-free survival (RFS) durations, utilizing 16S rRNA sequencing. Furthermore, we assessed the prognostic significance of circulating microbiome DNA (cmDNA) and examined the effects of exogenous butyrate supplementation on the chemosensitivity of CRC cell lines.ResultsOur 16S sequencing analysis revealed a reduction in microbial diversity within tumor samples of patients with resistance, as indicated by metrics such as observed taxonomic units, Shannon, and Simpson indices. Notably, Roseburia and Fusobacteria emerged as prominent biomarkers for the resistance group, whereas Bifidobacterium, Helicobacter, and Akkermansia were identified as biomarkers for the non-resistant group. Utilizing a Lasso regression model, we identified six genera-Roseburia, Helicobacter, Gardnerella, Flavonifractor, Coprococcus, and Anaerostipes-that significantly correlated with recurrence-free survival. Furthermore, both the intratumor microbiome signature and circulating microbiome DNA were effective in accurately predicting CRC resistance. Experimental assays, including CCK8 and wound-healing, demonstrated that intratumor microbiome-derived butyrate enhances the proliferation and migration of HCT15 cells in a time- and concentration-dependent manner. Cell survival analysis further indicated that butyrate treatment significantly increased the IC50 value, suggesting heightened drug resistance in HCT15 cells. Mechanistically, this resistance was attributed to butyrate’s activation of the PI3K-AKT signaling pathway.ConclusionOur results suggest that intratumor microbiome-derived butyrate contributes to chemoresistance in colorectal cancer, highlighting the potential prognostic and therapeutic significance of the intratumor microbiome.https://www.frontiersin.org/articles/10.3389/fphar.2024.1510851/fullcolorectal cancerchemoresistancemicrobiomebutyratebiomarkers
spellingShingle Linsheng Xu
Linsheng Xu
Bingde Hu
Jingli He
Xin Fu
Na Liu
Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
Frontiers in Pharmacology
colorectal cancer
chemoresistance
microbiome
butyrate
biomarkers
title Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
title_full Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
title_fullStr Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
title_full_unstemmed Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
title_short Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
title_sort intratumor microbiome derived butyrate promotes chemo resistance in colorectal cancer
topic colorectal cancer
chemoresistance
microbiome
butyrate
biomarkers
url https://www.frontiersin.org/articles/10.3389/fphar.2024.1510851/full
work_keys_str_mv AT linshengxu intratumormicrobiomederivedbutyratepromoteschemoresistanceincolorectalcancer
AT linshengxu intratumormicrobiomederivedbutyratepromoteschemoresistanceincolorectalcancer
AT bingdehu intratumormicrobiomederivedbutyratepromoteschemoresistanceincolorectalcancer
AT jinglihe intratumormicrobiomederivedbutyratepromoteschemoresistanceincolorectalcancer
AT xinfu intratumormicrobiomederivedbutyratepromoteschemoresistanceincolorectalcancer
AT naliu intratumormicrobiomederivedbutyratepromoteschemoresistanceincolorectalcancer